|Bid||5.90 x 0|
|Ask||6.33 x 0|
|Day's Range||5.96 - 6.15|
|52 Week Range||2.75 - 14.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.25|
LONDON, UK / ACCESSWIRE / December 14, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Oncolytics Biotech, Aurinia ...
Aurinia Pharmaceuticals Inc., announced today that it has been selected for addition to the NASDAQ Biotechnology Index® , which will become effective prior to market open on Monday, December 18, 2017.
Aurinia Pharmaceuticals Inc. has released its financial results for the third quarter ended September 30, 2017. Amounts, unless specified otherwise, are expressed in U.S.
NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...
Aurinia Pharmaceuticals Inc. today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease .
Aurinia Pharmaceuticals (AUPH) needs Investors to pay close attention to the stock based on moves in the options market lately.
Aurinia Pharmaceuticals Inc., today announced it has received this year’s National Corporate Visionary Award from the Lupus Foundation of America. The award was presented to Dr.
LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...